AstraZeneca filed a request with the Patent Office (PO) for the publication in the PO’s official bullet of a court judgment invalidating a previous PO’s decision regarding the termination of one of AstraZeneca’s patents. The PO denied AstraZeneca’s request for publication due to a pending procedure for the issuance of a supplementary protection certificate (SPC) ensuing to that patent, the completion of which the PO considered as prejudicial to the publication. The Supreme Administrative Court – as the highest instance – held that the procedure was not prejudicial and obliged the PO to make the publication.

A summary of this case will be posted on


To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law

The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

Kluwer IP Law
This page as PDF